Records 1-30 (of 81 Records) |
Query Trace: TLR7[original query] |
---|
Relationship of toll-like receptor 7, 9 and 10 polymorphisms on the severity of COVID-19. Bayyurt Burcu, et al. Japanese journal of infectious diseases 2024 0 0. |
Evaluation of Genetic or Cellular Impairments in Type I IFN Immunity in a Cohort of Young Adults with Critical COVID-19. Covill L E, et al. Journal of clinical immunology 2024 0 0. (2) 50 |
The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants. Naushad Shaik Mohammad, et al. Scientific reports 2023 0 0. (1) 13078 |
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Daniela Matuozzo et al. Genome medicine 2023 4 (1) 22
We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5–528.7, P?=?1.1?×?10-4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR?=?3.70[95%CI 1.3–8.2], P?=?2.1?×?10-4).
|
Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. García-García Ana, et al. The Journal of experimental medicine 2023 0 0. (5) |
SARS-CoV-2 Variant-Specific mRNA Vaccine: Pros and Cons. Shahsavandi Shahla, et al. Viral immunology 2023 0 0. |
The investigation of host genetic variants of toll-like receptor 7 and 8 in COVID-19. Bagci Gokhan, et al. Nucleosides, nucleotides & nucleic acids 2023 0 0. 1-17 |
"Immunological evaluation of unvaccinated young patients with Turner Syndrome after COVID-19". de Castro Mateus V, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023 0 0. |
Differential activation of human neutrophils by SARS-CoV-2 variants of concern. Lebourgeois Samuel, et al. Frontiers in immunology 2022 0 0. 1010140 |
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. Sokal Aurélien, et al. The Journal of experimental medicine 2022 0 0. (1) |
Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics. Cao Jun-Feng, et al. Frontiers in microbiology 2022 0 0. 1013911 |
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Matuozzo Daniela, et al. medRxiv : the preprint server for health sciences 2022 0 0. |
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. Butler-Laporte Guillaume, et al. PLoS genetics 2022 0 0. (11) e1010367 |
Effect of Toll-Like Receptor 7 Gene Polymorphism and ABO Blood Groups on the Severity of COVID-19 Patients. Al-Tamimi Zainab H D, et al. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH 2022 0 0. (3) 191-195 |
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with critical COVID-19 D Matuozo et al, MEDRXIV, October 25, 2022
We report here a genome-wide rare variant burden association analysis in 3,269 unvaccinated patients with life-threatening COVID-19 (1,301 previously reported and 1,968 new patients), and 1,373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI:1.5-528.7, P=1.1x10-4), in analyses restricted to biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR=3.70 [95%CI:1.3-8.2], P=2.1x10-4).
|
Sex-biased expression of the TLR7 gene in severe COVID-19 patients: Insights from transcriptomics and epigenomics. Gómez-Carballa A, et al. Environmental research 2022 0 0. 114288 |
Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. van der Made Caspar I et al. Genome medicine 2022 8 (1) 96 |
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative GB Laporte et al, MEDRXIV, July 20, 2022
We combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease.
|
Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern. Zhang Ru-Yan, et al. ACS infectious diseases 2022 0 0. |
Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. Zhang Qian, et al. The Journal of experimental medicine 2022 0 0. (8) |
Host genetic basis of COVID-19: from methodologies to genes. Zguro Kristina, et al. European journal of human genetics : EJHG 2022 0 0. |
Host genetic basis of COVID-19: from methodologies to genes K Zguro et al, EJHG, May 27, 2022
This review delineates GWAS and Burden test as traditional methodologies employed so far for the discovery of the human genetic basis of COVID-19, with particular attention to recently emerged predictive models such as the post-Mendelian model. A summary table with the main genome-wide significant genomic loci is provided. Besides, various common and rare variants identified in genes like TLR7, CFTR, ACE2, TMPRSS2, TLR3, and SELP are further described in detail to illustrate their association with disease severity.
|
Identification of a Potential mRNA-based Vaccine Candidate against the SARS-CoV-2 Spike Glycoprotein: A Reverse Vaccinology Approach. Durojaye Olanrewaju Ayodeji, et al. ChemistrySelect 2022 0 0. (7) e202103903 |
Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine. Atalis Alexandra, et al. Journal of controlled release : official journal of the Controlled Release Society 2022 0 0. |
mRNA expression of toll-like receptors 3, 7, 8, and 9 in the nasopharyngeal epithelial cells of coronavirus disease 2019 patients. Bagheri-Hosseinabadi Zahra, et al. BMC infectious diseases 2022 0 0. (1) 448 |
Individual Genetic Variability Mainly of Proinflammatory Cytokines, Cytokine Receptors and Toll-like receptors Dictates Pathophysiology of COVID-19 Disease. Vakil Mohammad Kazem, et al. Journal of medical virology 2022 0 0. |
Artificial Neural Network-Based Study Predicts GS-441524 as a Potential Inhibitor of SARS-CoV-2 Activator Protein Furin: a Polypharmacology Approach. Dhanalakshmi M, et al. Applied biochemistry and biotechnology 2022 0 0. |
COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities. El-Hefnawy Sally M, et al. Gene reports 2022 0 0. 101612 |
Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals. Gray Paul E, et al. Clinical & translational immunology 2022 0 0. (4) e1365 |
Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern. Rothen Dominik A, et al. Allergy 2022 0 0. |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 19, 2024
- Content source: